Compliance therapy for schizophrenia
Schizophrenia is a severe mental illness characterised by delusions and hallucinations. Antipsychotic drugs does reduce these symptoms, but at least half of people given these drugs do not comply with the treatment regimen prescribed. To assess the effects of compliance therapy on antipsychotic medi...
Saved in:
Published in: | Cochrane database of systematic reviews no. 3; p. CD003442 |
---|---|
Main Authors: | , , , |
Format: | Journal Article |
Language: | English |
Published: |
England
19-07-2006
|
Subjects: | |
Online Access: | Get more information |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | Schizophrenia is a severe mental illness characterised by delusions and hallucinations. Antipsychotic drugs does reduce these symptoms, but at least half of people given these drugs do not comply with the treatment regimen prescribed.
To assess the effects of compliance therapy on antipsychotic medication adherence for people with schizophrenia.
Cochrane Schizophrenia Group Trials Register (June 2005).
We included all randomised controlled trials of 'compliance therapy' for people with schizophrenia or related severe mental disorders.
We independently extracted data and, for dichotomous data, calculated the relative risk (RR), its 95% confidence interval (CI) on an intention to treat basis. We present continuous data using the weighted mean difference statistic.
We included one trial with relevant and available data (n=56, duration 2 years) comparing compliance therapy with non-specific counseling. The primary outcome 'non-compliance with treatment' showed no significant difference between compliance therapy and non-specific counseling (n=56, RR 1.23 CI 0.74 to 2.05). The compliance therapy did not substantially effect attitudes to treatment (n=50, WMD DAI score -2.10 CI -6.11 to 1.91). Very few people (~10%) left the study by one year (n=56, RR 0.5 CI 0.1 to 2.51). Mental state seemed unaffected by the therapy (n=50, WMD PANSS score 6.1 CI -4.54 to 16.74) as was insight (n=50, WMD SAI -0.5 CI -2.43 to 1.43), global functioning (n=50, WMD GAF -4.20 CI -16.42 to 8.02) and quality of life (n=50, WMD QLS -3.40 CI -16.25 to 9.45). At both one and two years the average number of days in hospital was non-significantly reduced for those allocated to the compliance therapy.
There is no clear evidence to suggest that compliance therapy is beneficial for people with schizophrenia and related syndromes but more randomised studies are justified and needed in order for this intervention to be fully examined. |
---|---|
AbstractList | Schizophrenia is a severe mental illness characterised by delusions and hallucinations. Antipsychotic drugs does reduce these symptoms, but at least half of people given these drugs do not comply with the treatment regimen prescribed.
To assess the effects of compliance therapy on antipsychotic medication adherence for people with schizophrenia.
Cochrane Schizophrenia Group Trials Register (June 2005).
We included all randomised controlled trials of 'compliance therapy' for people with schizophrenia or related severe mental disorders.
We independently extracted data and, for dichotomous data, calculated the relative risk (RR), its 95% confidence interval (CI) on an intention to treat basis. We present continuous data using the weighted mean difference statistic.
We included one trial with relevant and available data (n=56, duration 2 years) comparing compliance therapy with non-specific counseling. The primary outcome 'non-compliance with treatment' showed no significant difference between compliance therapy and non-specific counseling (n=56, RR 1.23 CI 0.74 to 2.05). The compliance therapy did not substantially effect attitudes to treatment (n=50, WMD DAI score -2.10 CI -6.11 to 1.91). Very few people (~10%) left the study by one year (n=56, RR 0.5 CI 0.1 to 2.51). Mental state seemed unaffected by the therapy (n=50, WMD PANSS score 6.1 CI -4.54 to 16.74) as was insight (n=50, WMD SAI -0.5 CI -2.43 to 1.43), global functioning (n=50, WMD GAF -4.20 CI -16.42 to 8.02) and quality of life (n=50, WMD QLS -3.40 CI -16.25 to 9.45). At both one and two years the average number of days in hospital was non-significantly reduced for those allocated to the compliance therapy.
There is no clear evidence to suggest that compliance therapy is beneficial for people with schizophrenia and related syndromes but more randomised studies are justified and needed in order for this intervention to be fully examined. |
Author | McIntosh, A M Lawrie, S M Conlon, L Stanfield, A C |
Author_xml | – sequence: 1 givenname: A M surname: McIntosh fullname: McIntosh, A M email: andrew.mcintosh@ed.ac.uk organization: University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK EH10 5HF. andrew.mcintosh@ed.ac.uk – sequence: 2 givenname: L surname: Conlon fullname: Conlon, L – sequence: 3 givenname: S M surname: Lawrie fullname: Lawrie, S M – sequence: 4 givenname: A C surname: Stanfield fullname: Stanfield, A C |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/16856009$$D View this record in MEDLINE/PubMed |
BookMark | eNo1jstKw0AUQAdR7EN_oWThNum9N_NcSrQqFLpRcFcmkzsk0jxIdFG_3oC6OosDh7MSl13fsRAbhAwBaItSK7TKZsUDQC4lZcNXSRdiOQuXSpe_L8Rqmj5m6RDttVigtkoDuKW4K_p2ODW-C5x81jz64ZzEfkymUDff_VCP3DX-RlxFf5r49o9r8bZ7fC2e0_3h6aW436dBAlIaITdaxhBUIMBYVuA4l57JWNaV1U4pY71kNESlkeyrcmZUyDbkJhKtxea3O_-3XB2HsWn9eD7-79IPA7pCww |
CitedBy_id | crossref_primary_10_1002_14651858_CD007768_pub3 crossref_primary_10_1017_S1134066500005725 crossref_primary_10_1016_j_jtcc_2008_02_006 crossref_primary_10_1111_j_1447_0349_2012_00889_x crossref_primary_10_1016_j_cpr_2016_10_009 crossref_primary_10_1016_j_ijnurstu_2008_10_010 crossref_primary_10_1002_14651858_CD004716_pub4 crossref_primary_10_2147_PPA_S349460 crossref_primary_10_1016_j_psc_2007_05_001 crossref_primary_10_1016_j_jclinepi_2008_04_005 crossref_primary_10_3109_01612840_2015_1058445 crossref_primary_10_1111_j_1447_0349_2009_00613_x crossref_primary_10_1192_apt_14_1_79 crossref_primary_10_1007_s11920_008_0057_7 crossref_primary_10_1111_inm_12089 crossref_primary_10_1002_14651858_CD006346 crossref_primary_10_1111_j_1758_5872_2010_00067_x crossref_primary_10_1111_jpm_12079 crossref_primary_10_1002_14651858_CD010646_pub3 crossref_primary_10_1186_s12888_016_0744_6 crossref_primary_10_1002_14651858_CD009960_pub2 crossref_primary_10_1111_j_1442_2018_2009_00440_x crossref_primary_10_1016_j_eurpsy_2007_09_003 crossref_primary_10_1111_j_1447_0349_2009_00649_x crossref_primary_10_1177_1078390318761790 crossref_primary_10_1016_j_mppsy_2007_07_002 crossref_primary_10_1111_j_1365_2850_2011_01809_x |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1002/14651858.CD003442.pub2 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1469-493X |
ExternalDocumentID | 16856009 |
Genre | Systematic Review Journal Article Review |
GroupedDBID | --- 53G 5GY 7PX 9HA ABJNI ACGFO ACGFS AENEX ALMA_UNASSIGNED_HOLDINGS ALUQN AYR CGR CUY CVF D7G ECM EIF HYE NPM OEC OK1 P2P RWY WOW ZYTZH |
ID | FETCH-LOGICAL-c4012-f03764fcc5c201fbd09e34ae278e6d8695578a4e1722b74eadb2b7f51e8c37f22 |
IngestDate | Sat Sep 28 08:30:32 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c4012-f03764fcc5c201fbd09e34ae278e6d8695578a4e1722b74eadb2b7f51e8c37f22 |
OpenAccessLink | https://europepmc.org/articles/pmc7017223?pdf=render |
PMID | 16856009 |
ParticipantIDs | pubmed_primary_16856009 |
PublicationCentury | 2000 |
PublicationDate | 20060719 |
PublicationDateYYYYMMDD | 2006-07-19 |
PublicationDate_xml | – month: 7 year: 2006 text: 20060719 day: 19 |
PublicationDecade | 2000 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Cochrane database of systematic reviews |
PublicationTitleAlternate | Cochrane Database Syst Rev |
PublicationYear | 2006 |
SSID | ssj0039118 |
Score | 2.0681274 |
SecondaryResourceType | review_article |
Snippet | Schizophrenia is a severe mental illness characterised by delusions and hallucinations. Antipsychotic drugs does reduce these symptoms, but at least half of... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | CD003442 |
SubjectTerms | Antipsychotic Agents - therapeutic use Confidence Intervals Humans Patient Compliance Recurrence Risk Schizophrenia - drug therapy |
Title | Compliance therapy for schizophrenia |
URI | https://www.ncbi.nlm.nih.gov/pubmed/16856009 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NT4MwFG82TYwX4_e34bCbQaEtUI4Lm9nBedlMvC1QXrOLsGQx_vu-0jLYMqMevMDSsgb4ld97r30fhPQARZQnZKAjlnOXK8BPiinfDTKpwjxOOUt1oPBoEr28icGQDzudeve8aftXpLENsdaRs39AezUoNuBvxByPiDoef4V7UvmIV4EAJrbKeGQu2851bY00KeUc5RXca19RLdO0-riZ37nRvMd64bpczg2nNFsYZWH371eLyc_pp63VNVkvWryqit23S7StRYfItdQGhijRrHZ5XNXyrecIaxFhMqiSCdKtLG2yvvq6DLsIxEN9rZ6Ba3_AN7t4r3DyQ6FVs_jn3o3s2XVXl3RRF9LqcjKuJTVDohd11LhHH7ffkE4rawfZMD0qFWR6SA6s7eD0DehHpAPFMdkbW--IE9JrsHcs9g5i76xhf0pen4bTZOTaKhiuRNuXuspDGcCVlIFEZU1luRcD4ynQSECYizAOkHRTDqiJ0iziyAwZnlXgg5AsUpSekZ2iLOCCOAzQvg1UiAOH3EtlxgHp3peQM5qD8i_JuXm-2cKkOpnVT371bc812W8myA3ZVfgdwS3pLvOPu-ptfwFPtTkW |
link.rule.ids | 782 |
linkProvider | EBSCOhost |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Compliance+therapy+for+schizophrenia&rft.jtitle=Cochrane+database+of+systematic+reviews&rft.au=McIntosh%2C+A+M&rft.au=Conlon%2C+L&rft.au=Lawrie%2C+S+M&rft.au=Stanfield%2C+A+C&rft.date=2006-07-19&rft.eissn=1469-493X&rft.issue=3&rft.spage=CD003442&rft_id=info:doi/10.1002%2F14651858.CD003442.pub2&rft_id=info%3Apmid%2F16856009&rft_id=info%3Apmid%2F16856009&rft.externalDocID=16856009 |